Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody response to a third BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed to achieve a humoral resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Herishanu, Yair, Rahav, Galia, Levi, Shai, Braester, Andrei, Itchaki, Gilad, Bairey, Osnat, Dally, Najib, Shvidel, Lev, Ziv-Baran, Tomer, Polliack, Aaron, Tadmor, Tamar, Benjamini, Ohad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648353/
https://www.ncbi.nlm.nih.gov/pubmed/34861036
http://dx.doi.org/10.1182/blood.2021014085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648353/
https://www.ncbi.nlm.nih.gov/pubmed/34861036
http://dx.doi.org/10.1182/blood.2021014085

Ejemplares similares